This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication


Study: GZ17-6.02 kills PDX isolates of uveal melanoma

GZ17-6.02 kills PDX isolates of uveal melanoma
Control data for transfection efficiency of uveal melanoma cells. Credit: Oncotarget (2024). DOI: 10.18632/oncotarget.28586

A new research paper titled "GZ17-6.02 kills PDX isolates of uveal melanoma" has been published in Oncotarget.

In this new study, researchers Laurence Booth, Jane L. Roberts, Ivan Spasojevic, Kaitlyn C. Baker, Andrew Poklepovic, Cameron West, John M. Kirkwood, and Paul Dent from Virginia Commonwealth University, Duke University School of Medicine, Genzada Pharmaceuticals, Texas Tech University Health Sciences Center, and University of Pittsburgh Cancer Institute defined the biology of GZ17-6.02 in UM cells and in parallel determined its interaction with irreversible ERBB inhibitors (afatinib, neratinib) and with the cytotoxic agent doxorubicin.

"GZ17-6.02 is a novel compound, containing the synthetically manufactured components: curcumin, harmine and isovanillin and has undergone phase I safety evaluation in ," the researchers state.

GZ17-6.02 has indeed undergone phase I evaluation in patients with . The RP2D is 375 mg PO BID, with an uveal melanoma patient exhibiting a 15% reduction in tumor mass for 5 months at this dose. Studies in this manuscript have defined the biology of GZ17-6.02 in PDX isolates of uveal melanoma cells.

GZ17-6.02 killed uveal melanoma cells through multiple convergent signals including enhanced ATM-AMPK-mTORC1 activity, inactivation of YAP/TAZ and inactivation of eIF2α. GZ17-6.02 significantly enhanced the expression of BAP1, predictive to reduce metastasis, and reduced the levels of ERBB family RTKs, predicted to reduce growth. GZ17-6.02 interacted with doxorubicin or ERBB family inhibitors to significantly enhance tumor cell killing which was associated with greater levels of autophagosome formation and autophagic flux.

Knock-down of Beclin1, ATG5 or eIF2α were more protective than knock-down of ATM, AMPKα, CD95 or FADD; however, overexpression of FLIP-s provided greater protection compared to knock-down of CD95 or FADD. Expression of activated forms of mTOR and STAT3 significantly reduced tumor cell killing. GZ17-6.02 reduced the expression of PD-L1 in uveal melanoma cells to a similar extent as observed in cutaneous melanoma cells whereas it was less effective at enhancing the levels of MHCA. The components of GZ17-6.02 were detected in tumors using a syngeneic tumor model.

"Our data support future testing GZ17-6.02 in as a single agent, in combination with ERBB family inhibitors, in combination with cytotoxic drugs, or with an anti-PD1 immunotherapy," the researchers conclude.

More information: Laurence Booth et al, GZ17-6.02 kills PDX isolates of uveal melanoma, Oncotarget (2024). DOI: 10.18632/oncotarget.28586

Journal information: Oncotarget
Provided by Impact Journals LLC
Citation: Study: GZ17-6.02 kills PDX isolates of uveal melanoma (2024, May 22) retrieved 19 July 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

GZ17-6.02 with proteasome inhibitors kills multiple myeloma cells


Feedback to editors